Abstract Objectives: The peri-operative use of antiplatelet, anticoagulant and other drugs for patients undergoing carotid endarterectomy (CEA) is unclear and consensus is lacking. This study aimed to assess the current peri-operative practice of European vascular surgeons with respect to antiplatelet and other medications for patients undergoing CEA. Design: Online questionnaire study. Results: Partial or complete responses were received from 399/650 (61.4%) surgeons with a collective annual throughput of >11500 CEA procedures. For symptomatic and asymptomatic patients, 20/392 (5%) and 47/392 (12%) of surgeons would stop aspirin before surgery and 170/ 392 (43%) and 217/392 (55%) of surgeons would stop Clopidogrel prior to CEA. Of surgeons who would stop Clopidogrel, 84/170 (49%) and 124/217 (57%) would do so >7 days before surgery for symptomatic and asymptomatic patients respectively. 12/393 (3%) surgeons would prescribe one 75 mg dose of Clopidogrel on the evening before surgery. Intra-operative Dextran was used selectively by 40/395 (10%). Only 78/393 (20%) would delay surgery to commence a statin. Intra-operatively, 348/394 (88%) used intravenous heparin, which was reversed routinely by 47/348 (13%) and selectively by 60/348 (17%).
Introduction
Numerous large randomized studies including the North American Symptomatic Carotid Endarterectomy Trial (NASCET), 1 the European Carotid Surgery Trial (ECST) 2 and the Asymptomatic Carotid Surgery Trial (ACST) 3 have evaluated the effectiveness of carotid endarterectomy in patients with significant internal carotid artery stenosis. These have demonstrated a significant reduction in the risk of death or disabling strokes for patients randomized to surgery in comparison to those in the non-surgical arms. However, consensus is lacking on the peri-operative prescription of antiplatelet, cholesterol lowering or other medications for patients requiring carotid endarterectomy (CEA). A recent meta-analysis reported that aspirin was protective in most patients at increased risk of occlusive vascular events. 4 Furthermore, large randomized clinical studies have demonstrated reductions in stroke and death rates in patients treated with aspirin after stroke. 5 These findings suggest that a period of pre-operative administration followed by post-operative administration of aspirin may have a protective effect in patients undergoing CEA.
In order to maintain low complication rates following CEA, multiple components of the pre, intra and postoperative care must be carefully managed. Tsurgical technique and appropriate use hese factors include patient selection, assessment of cardiac risk factors, precise blood pressure control, meticulous of antiplatelet, anticoagulation and other medications. The aim of this study was to evaluate the use of peri-operative antiplatelet, anticoagulant and other medications amongst European Vascular Surgeons.
Materials and Methods
An email invitation to complete an online 16-part questionnaire was sent to all listed members of the European Society of Vascular Surgery (ESVS) and the Vascular Society of Great Britain and Ireland (VSGBI). The societies were not involved in the design of the study. Questions relating to the pre, peri and post-operative pharmacological management of patients undergoing CEA were devised by the study authors (Appendix 1). Questions related to pre-operative antiplatelet, anticoagulant and statin use; intra-operative heparin, dextran, protamine and dexamethasone use and post-operative antiplatelet use. The initial invitation email was sent in March 2008 and a reminder email was sent in June 2008. The questionnaire responses were anonymized and only one response per email address was allowed by the online academic survey software (Bristol Online Surveys). All complete and partially completed responses were included in the analysis and the number of completed responses received for each question is presented as the denominator. Statistical analysis was performed using the Chi Square test (SPSS v16.0, Chic, IL, USA). 
Results

Partial
Intra-operative management
Only 13/394 (3.2%) surgeons would give intra-operative pooled platelets if the patient was on dual antiplatelet 
Post-operative management
Among the surgeons who would discontinue antiplatelet drugs, 18/20 (90.0%) would restart aspirin and 131/189 (69.3%) would restart Clopidogrel on first day post-operatively ( Table 2) .
Discussion
This survey demonstrated that the majority of European Vascular Surgeons who responded would continue aspirin, but most would stop other antiplatelet and anticoagulant medications prior to carotid endarterectomy. Moreover, most respondents would use heparin intra-operatively, aim to maintain normal blood pressure during surgery and restart antiplatelet medications on the first post-operative day. Although a broad consensus was seen, it is worth noting that some variation in the clinical practice of European Vascular Surgeons was demonstrated in this study, highlighting the scarcity of level 1 evidence or clinical guidelines in this area. The decision to continue to stop antiplatelet and anticoagulant drugs requires the clinician to evaluate the risks and benefits for each individual patient and balance the risks of bleeding and thrombosis. In a study that investigated the use of 75 mg of Clopidogrel in addition to 150 mg of aspirin, a significant reduction in peri-operative emboli was seen without any increase in bleeding complications or blood transfusion. 6 A recent systematic review found that the risk of peri-operative stroke among those receiving antiplatelet agents was significantly reduced in comparison with the risk for those not receiving antiplatelet therapy, but that the risks of peri-operative death in the two groups were not significantly different. 7 Another study suggested that a single 75-mg dose of Clopidogrel, taken the evening before carotid endarterectomy, may reduce post-operative embolisation, a marker of thrombo-embolic stroke. 8 Moreover, a recent meta-analysis suggested that the use of Dipyridamole in combination with aspirin may be the best choice for secondary prevention of vascular events after stroke or TIA. 9 Despite these studies, 5e12% of surveyed surgeons would stop aspirin and more than half would stop Clopidogrel pre-operatively. Clearly, further clinical studies demonstrating clear benefits are needed before dual antiplatelet therapy is widely adopted by surgeons performing CEA.
Interestingly, a small proportion of surgeons would delay carotid endarterectomy for a week or more in order to give statins. The use of statins has been suggested as a potential method of plaque stabilization prior to CEA, a hypothesis supported by histological studies. 10 Clinical studies have also shown lower rates of adverse events in patients taking statins prior to CEA. 8 Interestingly, large studies have suggested that this benefit is greatest in symptomatic rather than asymptomatic patients. 11, 12 In a retrospective study, McGirt et al. suggested that peri-operative statin use (at least for one week before surgery and one month after) may reduce the incidence of cerebrovascular events and mortality among patients undergoing CEA. 13 A further study demonstrated that 4 weeks of treatment with atorvastatin resulted in significant local and systemic reductions in inflammatory mediators in patients undergoing carotid endarterectomy. These findings suggest that statins may reduce atherosclerotic plaque inflammation and potentially delay or prevent plaque rupture.
14 These observations are intriguing, but more definitive studies are needed before broad recommendations can be agreed. A strategy of delaying CEA for the administration of statins may seem logical in asymptomatic patients, but may be detrimental in symptomatic patients. The increasingly widespread use of statins in high-risk populations is likely to mean that the vast majority of patients requiring CEA will already be on cholesterol lowering medication.
The maintenance of hypertension (around 20% above pre-operative systolic pressure) during CEA may be justified by fears of 'watershed' stroke during carotid crossclamping 15 and evidence from patients undergoing awake CEA where neurological deficits may be reversed by elevation of arterial pressure. 16 However, most clinicians would agree that absolute values or targets should be viewed as guidelines only and adapted to individual patients, 17 particularly as augmentation of arterial pressure may be associated with increased risks, including a higher incidence of myocardial infarction 18 and intracerebral haemorrhage. 19 Dextran is thought to prevent platelet adherence to the endarterectomy site, although its role in CEA remains unclear. There is evidence to suggest that dextran 40 may reduce the incidence of post-operative emboli and stroke (assessed using transcranial Doppler). 20 Corticosteroids (dexamethasone 24e40 mg/day in divided doses) may reduce vasogenic cerebral oedema, but their routine use in treatment of ischaemic strokes is doubtful. 21 Studies evaluating peri-operative corticosteroids in patients treated with CEA are scarce, although a recent randomized trial did suggest that dexamethasone may be effective in reducing the incidence of temporary cranial nerve injuries during CEA. 22 We recognize that survey studies are often limited by poor response rates. The response rate in this study was only 61%, although this compares favourably with other similar studies. 23 Moreover, it is likely that a large number of surgeons (not members of ESVS or VSGBI) were not included and heterogeneity in clinical practice across Europe may limit the generalisability of this study. Another limitation of this study was the lack of questions on the management of patients taking dual antiplatelet medications, which is an increasingly common clinical scenario. In conclusion, there appears to be broad consensus between vascular surgeons in the use of antiplatelet and statins for patients undergoing carotid endarterectomy, although some variations do exist. Only by establishing evidence-based guidelines can we achieve greater consistency of treatment for this patient group. 
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